Goodwin Procter·IP / PATENT

First BPCIA Suit Filed Over ENTYVIO Biosimilar

Takeda filed the first-ever BPCIA patent infringement lawsuit over a proposed biosimilar for its blockbuster drug ENTYVIO (vedolizumab), targeting Polpharma Biologics in New Jersey federal court.

bpciabiosimilarspatent-litigationpharma-biotechtakedaentyviopolpharma

Read the original firm alert → Tuesday, September 1, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.